Vonovia SE (VNNVF)

Inozyme Pharma Revenue

Vonovia SE had revenue of 1.57B EUR in the quarter ending June 30, 2025, with 7.46% growth. This brings the company's revenue in the last twelve months to 7.71B, up 27.72% year-over-year. In the year 2024, Vonovia SE had annual revenue of 7.03B with 16.71% growth.

• Revenue (ttm): 7.71B EUR
• Revenue Growth: +27.72%
• P/S Ratio: 3.05
• Revenue / Employee: 606.26K EUR
• Employees: 12,720
• Market Cap: 27.65B USD

Revenue Chart

* This company reports financials in EUR.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	7.03B	1.01B	16.71%
Dec 31, 2023	6.02B	-2.27B	-27.36%
Dec 31, 2022	8.29B	3.01B	56.94%
Dec 31, 2021	5.28B	1.25B	30.93%
Dec 31, 2020	4.03B	362.30M	9.87%